Short answer
Charles River Laboratories (CRL) filed its Q3 2025 10-Q quarterly report on Nov 5, 2025 for the quarter ended Sep 27, 2025. Quarterly revenue was $1.0B (down 0.5% year over year) with net income of $54M.
Q3 2025 key financials · XBRL
- Revenue
- $1.0B
- −0.5% YoY · −2.6% QoQ
- Net income
- $54M
- −21.9% YoY · +4.0% QoQ
- Operating margin
- 13.3%
- EPS (diluted)
- $1.10
- −17.3% YoY · +4.8% QoQ
Source: XBRL data from the Charles River Laboratories (CRL) Q3 2025 10-Q on SEC EDGAR. USD.
Charles River Laboratories Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $1,004.9M, down 0.5% YoY from $1,009.8M; nine months revenue $3,021.2M, down 0.9% YoY from $3,047.4M
- Operating margin Q3 13.3% vs 11.6% YoY (up 170 bps); nine months margin 10.2% vs 13.0% YoY (down 280 bps)
- Best segment Q3: RMS revenue up 7.9% to $213.5M, operating margin 16.2% vs 13.9% YoY; worst segment Manufacturing nine months operating margin 7.6% vs 19.3% YoY (down 1,170 bps)
- Operating cash flow nine months $590.1M, up from $575.2M YoY; capital expenditures down to $130.2M from $157.4M YoY
- Management cites cautious client spending, DSA backlog decline, ongoing restructuring with $175M cost savings in 2025, $70M incremental savings in 2026 expected, SEC investigation ongoing, and strategic focus on acquisitions and divestitures
Risk Factors
- No newly added risk factors this quarter; most risks carry forward from 2024 10-K without material changes
- Most materially updated risk: Impact of U.S.-imposed tariffs on imports from Vietnam, Mauritius, China, still uncertain and affecting supply chain costs
- Regulatory risk: FDA plans to reduce animal testing in preclinical studies using NAMs, potentially impacting demand for traditional animal research services
- Operational risk: Lower-than-expected demand growth in 2024, leading to global restructuring actions and efficiency initiatives targeting $70M annual net cost savings
- Financial risk: Strategic review underway with focus on acquisitions, divestitures, and capital deployment amid potential stock price volatility and business disruption
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Charles River Laboratories quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.